Vazin Afsaneh, Heidaripour Mohammad Saleh, Kalantari Mohsen, Hatam Gholamreza
Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Research Center for Health Sciences, Institute of Health, Department of Vector Biology and Control of Diseases, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
J Parasit Dis. 2022 Jun;46(2):328-333. doi: 10.1007/s12639-022-01471-9. Epub 2022 Feb 11.
The appearance of resistance to pentavalent antimony, as the mainline of treatment for Cutaneous Leishmaniasis (CL) has been reported from Iran. According to the patients' laboratory and clinical history, 96 archived slides of patients infected with () treated with Meglumine Antimoniate (Glucantime®) were selected. After microscopic examination, Nested Polymerase Chain Reaction (Nested-PCR) and Restriction Fragment Length Polymorphism (RFLP) assays were done for each sample. In Nested-PCR, all positive samples were characterized as . Additionally, some positive products of sensitive, resistant, and recidivans cases were selected to check their differentiations by sequencing software. In RFLP, various patterns of schizodemes were detected according to the reference patterns. Most sensitive cases of (treated with Glucantime®) were categorized as schizodeme B, and most resistant cases were identified as schizodeme B and D. In recidivans cases, 91% of specimens categorized as schizodeme A and B. However, study on the type of isolates that are resistant or sensitive to Glucantime® could be helpful before drug therapy.
伊朗已报告出现对五价锑（皮肤利什曼病（CL）的主要治疗药物）的耐药情况。根据患者的实验室和临床病史，选择了96份用葡甲胺锑酸盐（Glucantime®）治疗的感染（）患者的存档玻片。经过显微镜检查后，对每个样本进行巢式聚合酶链反应（Nested-PCR）和限制性片段长度多态性（RFLP）分析。在巢式PCR中，所有阳性样本均被鉴定为。此外，选择了一些敏感、耐药和复发病例的阳性产物，通过测序软件检查它们的差异。在RFLP中，根据参考模式检测到不同的裂殖体模式。大多数敏感的（用Glucantime®治疗）病例被归类为裂殖体B型，大多数耐药病例被鉴定为裂殖体B型和D型。在复发病例中，91%的标本归类为裂殖体A型和B型。然而，在药物治疗前研究对Glucantime®耐药或敏感的分离株类型可能会有所帮助。
